Psychedelic Medicine

Association

Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada

Excerpts from the publication

Background
Psychedelic-assisted therapies are receiving mounting attention for their therapeutic potential. However, little is known about interest among women who experience elevated risk of mental health and substance use disorders. This study examined interest in receiving psychedelic-assisted therapy and socio-structural factors associated with interest among marginalized women.

Methods
Data (2016–2017) were drawn from two community-based, prospective open cohorts of >1000 marginalized women in Metro Vancouver, Canada. Bivariate and multivariable logistic regression examined associations with interest in receiving psychedelic-assisted therapy. Among women who used psychedelics, additional data were collected to describe ratings of personal meaningfulness, sense of wellbeing, and spiritual significance.

Results
Of 486 eligible participants (aged 20–67 years), 43% (n = 211) were interested in receiving psychedelic-assisted therapy. Over half identified as Indigenous (First Nations, Métis or Inuit). Factors independently associated with interest in psychedelic-assisted therapy in multivariable analysis included: daily crystal methamphetamine use in the last six months (Adjusted Odds Ratio [AOR] 3.02; 95%Confidence Interval (CI) 1.37–6.65), lifetime mental health conditions (depression, anxiety, post-traumatic stress disorder) (AOR 2.13; 95%CI 1.27–3.59), childhood abuse (AOR 1.99; 95%CI 1.02–3.88), lifetime psychedelic use (AOR 1.97; 95%CI 1.14–3.38), and younger age (AOR 0.97 per year older; 95%CI 0.95–0.99).

Conclusions
Several mental health and substance use-related variables that have been demonstrated to be amenable to psychedelic-assisted therapy were associated with interest in receiving psychedelic-assisted therapy among women in this setting. As access to psychedelic-assisted therapies continues to expand, any future approaches to extend psychedelic medicine to marginalized women should integrate trauma-informed care and broader socio-structural supports.

Read more

Psychedelics therapeutics: What we know, what we think, and what we need to research

Micro-dose, macro-impact: Leveraging psychedelics in frontline healthcare workers during the COVID-19 pandemic

Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review

Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review

Expectancy in placebo-controlled trials of psychedelics: if so, so what?

Ketamine in fibromyalgia: a systematic review